Resilience and Reinvention: Biotech’s Year of Maturity

Key Takeaways

• FDA CDER approved 55 novel drugs in 2023, 50 in 2024, and 46 in 2025, sustaining innovation after the 2020–2021 capital boom cooled.
• In 2024, CDER identified 24 of 50 novel drugs (48%) as first-in-class and 26 of 50 (52%) for rare or orphan diseases.
• 2026 SEC S-1 filings from companies such as Generate Biomedicines and Apnimed center on Phase 3 or NDA-stage assets, a maturity signal for public-market readiness.
• Resilience means selective capital access and pipeline focus; it does not prove a broad IPO boom has returned.

How many novel drugs has FDA CDER approved recently?

CDER’s Novel Drug Approvals tallies show durable product output across the funding reset. In 2023 the center approved 55 novel drugs never before marketed in the United States. In 2024 it approved 50, and in 2025 it approved 46.

Those counts track new molecular entities and therapeutic biologics under CDER’s remit and exclude many CBER biologics such as vaccines and some gene therapies. The three-year run still sits near the long-run average of about 47 novel approvals per year that CDER reported for 2015–2024.

Source: FDA Novel Drug Approvals for 2023; FDA Novel Drug Approvals for 2024; FDA Novel Drug Approvals for 2025.

What first-in-class and rare-disease mix signals reinvention?

Maturity is not only volume. CDER’s 2024 annual report said 24 of 50 novel drugs (48%) were first-in-class and 26 of 50 (52%) treated rare or orphan diseases affecting fewer than 200,000 people in the U.S.

That mix rewards modality depth—antibodies, oligonucleotides, and other specialized platforms—over broad early-stage storytelling. Business development teams should weight first-in-class and orphan labels when screening partners, because those cohorts often define differentiated IP and pricing pathways.

• 55 CDER novel approvals in 2023
• 50 CDER novel approvals in 2024, including 24 first-in-class
• 46 CDER novel approvals in 2025

Source: FDA Advancing Health Through Innovation: New Drug Therapy Approvals 2024/2025 report PDF.

How are 2026 biotech S-1 filings showing market maturity?

Public filings in 2026 illustrate a preference for clinical proof. Generate Biomedicines’ February 23, 2026 Form S-1/A describes a generative biology platform with three computationally engineered proteins in human testing, led by GB-0895, a long-acting anti-TSLP monoclonal antibody in pivotal Phase 3 asthma trials with first patient dosing on January 26, 2026.

Apnimed’s July 10, 2026 Form S-1 states that the company submitted an NDA for Oxnimbi (AD109) to FDA in April 2026 after two Phase 3 trials—LunAIRo and SynAIRgy—that together enrolled about 1,300 adults with obstructive sleep apnea.

Source: Generate Biomedicines Form S-1/A (SEC EDGAR, Feb. 23, 2026); Apnimed Form S-1 (SEC EDGAR, July 10, 2026).

Investment implications for business development teams

Resilience now means concentrating capital on assets with registrational or Phase 3 readouts, then using partnerships to fill modality gaps. Licensing and M&A screens should start from FDA approval calendars and SEC risk-factor language, not conference narratives alone.

Teams covering cardiometabolic and respiratory pipelines can cross-check Avalyn Pharma’s April 23, 2026 S-1/A, which describes inhaled formulations for rare lung disease and estimates about $181.8 million in net IPO proceeds at the $17.00 midpoint—another example of clinical-stage positioning for public markets.

Related coverage: Biotech IPOs surge and M&A activity, Lilly–Gilead pharma M&A boom analysis, and FDA decisions in Q2 2026.

What remains unproven about a full sector rebound

Steady CDER novel-approval counts do not prove that every biotech can raise equity on favorable terms. FDA tallies omit many CBER products and do not measure IPO proceeds, cash runway, or post-listing performance.

SEC S-1 documents are marketing filings subject to completion; they confirm company claims and stage, not underwriter success or aftermarket returns. Analysts should treat “maturity” as a pipeline and disclosure pattern, not a forecast of 2021-style issuance volume.

Related NovaPharma coverage

• Biotech IPOs surge amid M&A activity
• Lilly and Gilead drive pharma M&A boom
• China’s licensing boom and global pipelines

Frequently Asked Questions

Primary Sources

1. FDA Novel Drug Approvals for 2023
2. FDA Novel Drug Approvals for 2024
3. FDA Novel Drug Approvals for 2025
4. FDA New Drug Therapy Approvals annual report PDF
5. Generate Biomedicines Form S-1/A (SEC)
6. Apnimed Form S-1 (SEC)